NSE - Delayed Quote INR
Alpa Laboratories Limited (ALPA.NS)
108.16
-5.34
(-4.70%)
At close: April 25 at 3:29:25 PM GMT+5:30
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
964,768
1,079,185
924,102
1,105,133
964,135
Cost of Revenue
616,778
746,040
614,970
760,872
647,555
Gross Profit
347,990
333,145
309,132
344,261
316,580
Operating Expense
257,295
255,823
235,712
248,849
219,415
Operating Income
90,695
77,322
73,420
95,412
97,165
Net Non Operating Interest Income Expense
18,965
19,583
8,209
12,387
5,764
Pretax Income
266,721
206,820
158,903
195,620
107,865
Tax Provision
58,698
39,055
33,075
54,702
35,394
Net Income Common Stockholders
208,023
167,765
125,828
140,917
72,471
Diluted NI Available to Com Stockholders
208,023
167,765
125,828
140,917
72,471
Basic EPS
9.90
8.01
5.88
6.70
3.45
Diluted EPS
9.90
8.01
5.88
6.70
3.45
Basic Average Shares
21,097.93
21,040.60
21,040.60
21,040.60
21,041
Diluted Average Shares
21,097.93
21,040.60
21,040.60
21,040.60
21,041
Rent Expense Supplemental
--
712
626
702
600
Total Expenses
874,073
1,001,863
850,682
1,009,721
866,970
Net Income from Continuing & Discontinued Operation
208,023
167,765
125,828
140,917
72,471
Normalized Income
140,442.30
105,487.37
106,449.84
81,148.95
66,752.18
Interest Income
--
23,175
10,445
14,577
6,542
Interest Expense
3,844
3,226
825
1,069
261
Net Interest Income
18,965
19,583
8,209
12,387
5,764
EBIT
270,565
210,046
159,728
196,689
108,126
EBITDA
293,136
229,595
173,020
213,256
120,426
Reconciled Cost of Revenue
616,778
746,040
614,970
760,872
647,555
Reconciled Depreciation
22,571
19,549
13,292
16,567
12,300
Net Income from Continuing Operation Net Minority Interest
208,023
167,765
125,828
140,917
72,471
Total Unusual Items Excluding Goodwill
86,650
86,281
26,847
82,969
7,923
Total Unusual Items
86,650
86,281
26,847
82,969
7,923
Normalized EBITDA
206,486
143,314
146,173
130,287
112,503
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
19,069.30
24,003.37
7,468.84
23,200.95
2,204.18
3/31/2021 - 8/6/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
BALPHARMA.BO Bal Pharma Limited
107.51
-1.02%
LASA.NS Lasa Supergenerics Limited
17.22
-3.53%
ZENOTECH.BO Zenotech Laboratories Limited
58.01
-1.71%
MEDICO.NS Medico Remedies Limited
56.08
-5.67%
AMBALALSA.BO Ambalal Sarabhai Enterprises Limited
37.95
-3.75%
NOVARTIND.BO Novartis India Limited
818.35
-0.84%
BLISSGVS.NS Bliss GVS Pharma Limited
121.87
-3.57%
ERIS.NS Eris Lifesciences Limited
1,468.20
-2.90%
ALKEM.NS Alkem Laboratories Limited
5,033.50
-3.22%
TORNTPHARM.NS Torrent Pharmaceuticals Limited
3,238.90
-2.59%